Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

(2022) Sue Ann Costa Clemens et al.   LANCET

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

(2022) Delphine Planas et al.   NATURE

Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants

(2022) Kang Wang et al.   NATURE

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

(2022) Peter B. Gilbert et al.   SCIENCE

Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study

(2022) Alejandro Jara et al.   Lancet Global Health

SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond

(2022) Sean Wei Xiang Ong et al.   Expert Review of Respiratory Medicine

Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections

(2022) Salomé Desmecht et al.   Frontiers in Immunology

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

(2022) Jing-Xin Li et al.   Lancet Respiratory Medicine

Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine

(2022) Raquel Herrera-Comoglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19

(2022) Philipe Gobeil et al.   Nature Communications

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia

(2021) Douglas B. Cines et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

(2021) Andreas Greinacher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

(2021) Nicole Doria-Rose et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prior infection and age impacts antibody persistence after SARS-CoV-2 mRNA vaccine

(2021) Elizabeth Fraley et al.   CLINICAL INFECTIOUS DISEASES

COVID vaccine immunity is waning — how much does that matter?

(2021) Elie Dolgin   NATURE

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination

(2021) Dan H. Barouch et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects

(2021) Davide Ferrari et al.   VACCINE

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine

(2021) Yunlong Cao et al.   CELL RESEARCH

Trying to Block SARS-CoV-2 Transmission With Intranasal Vaccines

(2021) Rita Rubin   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

(2021) Ritthideach Yorsaeng et al.   VACCINE

Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections

(2021) Liyana Ahmad   Frontiers in Immunology

Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system

(2017) Jianhui Nie et al.   Scientific Reports